Cytotoxic Drugs

A Detailed Explanation of ADC: How ADC is Reshaping Clinical Guidelines? A New Era in Lung Cancer Treatment

by
A Detailed Explanation of ADC: How ADC is Reshaping Clinical Guidelines? A New Era in Lung Cancer Treatment

In 2019, a CT imaging comparison from Gustave Roussy Hospital in Paris, France, caused a stir in the oncology community: a late-stage non-small cell lung cancer patient, who had failed both chemotherapy and immunotherapy, showed significant reduction in systemic metastatic lesions just two months after being enrolled in the clinical trial of Trastuzumab Deruxtecan (T-DXd), … Read more

What Are ADC Drugs? Which Breast Cancer Patients Can Receive ADC Treatment?

by
What Are ADC Drugs? Which Breast Cancer Patients Can Receive ADC Treatment?

Breast cancer, regarded as the “killer of beauty,” is a malignant tumor that severely threatens women’s health, with an increasing incidence year by year. Antibody-drug conjugates (ADC), as a new type of therapeutic drug, have become a hot research topic in the field of breast cancer due to their advantages of “high efficacy and low … Read more

Design Mechanisms and Adverse Reaction Management of Antibody-Drug Conjugates (ADCs)

by
Design Mechanisms and Adverse Reaction Management of Antibody-Drug Conjugates (ADCs)

Introduction: Antibody-drug conjugates (ADC) consist of antibodies, linkers, and small molecule cytotoxic drugs, combining high specificity and high cytotoxicity advantages. However, their structural diversity and complexity, along with the low content of released small molecule toxins in the circulatory system, pose significant challenges for pharmacokinetic studies. This article will discuss the mechanisms, design, safety features, … Read more

Review of ADC Drugs: Current Status and Future Directions

by
Review of ADC Drugs: Current Status and Future Directions

Antibody-Drug Conjugates (ADCs) are one of the fastest-developing treatments in the field of oncology, with 15 ADCs already approved and over 210 currently undergoing clinical trials. In recent years, the development of ADC drugs has entered a flourishing phase, especially demonstrating significant efficacy and good safety profiles against targets such as HER2, EGFR, Trop2, CLDN18.2, … Read more